A report released today by Bankhaus Lampe KG about Bayer (ETR:BAYN) ups the target price to 103.00EUR
- Updated: September 15, 2016
Only yesterday Bayer (ETR:BAYN) traded 0.00% even at 91.44EUR. BAYN’s 50-day average is 0.04EUR and its 200-day average is 0.03EUR. With the last stock close up 1.82% relative to the 200-day moving average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the date range. Volume of trade was was down over the average, with 0 shares of BAYN changing hands under the typical 211 shares..
Bankhaus Lampe KG bumped the estimated target of Bayer (ETR:BAYN) to 103EUR, stating a possible upside of 0.13%,
On 8/29/2016, Citigroup Corp. reported on Bayer(ETR:BAYN) raised the target price from 0.00EUR to 120.00EUR. At the time, this suggested an upside of 0.24%.
Bayer has a one-year low of 0.03EUR and a one-year high of 0.04EUR. The company’s total market value is currently 0.0 EUR.
General Company Details For Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, and adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.